Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection Carpuject™ Units and Labetalol Hydrochloride Injection, USP Carpuject™ Units Due To The Potential For Incomplete Crimp Seals - Press Release
Portfolio Pulse from Benzinga Newsdesk
Hospira Inc., a subsidiary of Pfizer Inc., has issued a voluntary nationwide recall for Buprenorphine Hydrochloride Injection Carpuject™ Units and Labetalol Hydrochloride Injection, USP Carpuject™ Units due to the potential for incomplete crimp seals.
May 21, 2024 | 8:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pfizer Inc.'s subsidiary, Hospira Inc., has issued a voluntary recall for certain injection units due to potential incomplete crimp seals. This recall could impact Pfizer's stock in the short term due to potential regulatory scrutiny and product safety concerns.
The recall of medical products due to safety concerns can lead to regulatory scrutiny and potential financial implications for Pfizer. This could negatively impact investor sentiment and Pfizer's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100